Carlyle's $4B Purchase Of Baxter's Kidney Division Backed By Ares And HPS Financing
Portfolio Pulse from Vandana Singh
Carlyle Group's potential $4 billion acquisition of Baxter International's kidney-care division is being financed by Ares Management and HPS Investment Partners with a $3 billion credit facility. The deal, which includes a $2.5 billion unitranche loan and a $450 million revolver, is still under negotiation. Baxter's Vantive division generated $4.5 billion in revenue in 2023.
July 24, 2024 | 7:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ares Management is providing a $3 billion credit facility to finance Carlyle Group's potential acquisition of Baxter's kidney-care division.
Ares Management's involvement in a significant financing deal for a major acquisition could positively impact its stock price due to the potential for high returns and increased visibility.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Baxter International is in talks to sell its kidney-care division, Vantive, to Carlyle Group for over $4 billion, including debt.
The sale of a major division could streamline Baxter's operations and provide significant capital, potentially boosting its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Carlyle Group is in exclusive talks to acquire Baxter's kidney-care division for over $4 billion, including debt.
The potential acquisition of a high-revenue division could boost Carlyle Group's portfolio and future earnings, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90